Table 1.

Demographic and clinical data among patients with recent-onset psoriatic arthritis (PsA), psoriasis of the skin (Ps) and healthy control participants.

Characteristic	PsA (n=16)	Ps (n=15)	Healthy Controls (n=17)
Age, years, mean (median)	46.2 (40)	39.4 (37)	42.2 (39)
Female, %	56%	53%	64%
Ethnicity, white*	62%	66%	59%
HLA-B27, %	12%	n/a	n/a
HLA- Cw6, %	18%	n/a	n/a
HLA-B27 and/or Cw6, %	30%	n/a	n/a
Disease duration, months, mean (median)	0.8 (0)	16 (11)	n/a
Disease activity parameters (articular)
CRP, mg/l, mean (median)	7.5 (0)	1 (0)	0
DAS28, mean (median)	4.8 (4.7)	n/a	n/a
Patient VAS pain, mm, mean (median)	50.6 (45)	n/a	n/a
Active Joint Count, mean (median)	4.7 (3)	n/a	n/a
Axial involvement, %	25%	n/a	n/a
Disease activity parameters (skin)
PASI, mean (median)	5.2 (3.8)	6.3 (4.3)	n/a
Nail psoriasis, %	75%	69%	n/a
Medication use
NSAIDs, current, %	75%	0	n/a
Methotrexate, %	6%**	0	n/a
Prednisone, %	0	0	n/a
Biological agent, %	0	0	n/a

Abbreviations: PsA, psoriatic arthritis; Ps, psoriasis of the skin only; CRP, C-reactive protein; DAS28, Disease Activity Score with 28 joint count; VAS, visual analog scale; PASI, Psoriasis Area and Severity Index; NSAIDs, non-steroidal anti-inflammatory drugs.

^*Including Hispanic whites.

^**One patient had received one dose of methotrexate the week prior to enrollment.